Literature DB >> 9222941

Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension.

R S Khattar1, D U Acharya, C Kinsey, R Senior, A Lahiri.   

Abstract

OBJECTIVE: To determine the longitudinal relationship between clinic and ambulatory blood pressures and subsequent left ventricular and carotid artery structure.
DESIGN: A retrospective follow-up study.
SETTING: A large district general hospital in Harrow, UK. PATIENTS: One hundred and forty patients who had been subjected to 24 h ambulatory intra-arterial blood pressure monitoring on the basis of their having an elevated clinic blood pressure were followed up randomly a mean of 9.4 +/- 3.4 years later. The ambulatory blood pressure parameters measured were the mean systolic, mean diastolic and mean pulse pressures. Follow-up variables assessed included the clinic blood pressure, body mass index, total cholesterol, number of years of follow-up, left ventricular mass index, carotid intima-media thickness and carotid artery cross-sectional area. MAIN OUTCOME MEASURES: The left ventricular mass index, carotid intima-media thickness and carotid artery cross-sectional area.
RESULTS: The mean pulse pressure and mean systolic blood pressure were correlated significantly with the left ventricular mass index (r = 0.46, P < 0.001 and r = 0.36, P < 0.001, respectively), carotid intima-media thickness (r = 0.45, P < 0.001 and r = 0.37, P < 0.001, respectively) and carotid artery cross-sectional area (r = 0.46, P < 0.001 and r = 0.41, P < 0.001, respectively). The mean pulse pressure was associated independently with all three outcome measures. In addition, the body mass index was an independent determinant of the left ventricular mass index, whereas the serum cholesterol level was associated independently with the carotid artery cross-sectional area; the number of years of follow-up was related independently to the left ventricular mass index and carotid intima-media thickness, but not to the cross-sectional area.
CONCLUSIONS: These findings suggest that ambulatory blood pressure monitoring can play a role in guiding the choice of doses in drug therapy to limit potential target organ damage.

Entities:  

Mesh:

Year:  1997        PMID: 9222941     DOI: 10.1097/00004872-199715070-00005

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  16 in total

Review 1.  Using out of office blood pressure monitoring in the management of hypertension.

Authors:  P Verdecchia
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.

Authors:  Roberto Antonicelli; Stefano Omboni; Di Ciò Giovanni; Roberto Ansuini; Alfredo Mori; Rosaria Gesuita; Gianfranco Parati; Enrico Paciaroni
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity.

Authors:  Carolyn S P Lam; Jasmine Grewal; Barry A Borlaug; Steve R Ommen; Garvan C Kane; Robert B McCully; Patricia A Pellikka
Journal:  Hypertension       Date:  2010-03-09       Impact factor: 10.190

4.  Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community.

Authors:  Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

5.  Relationship of Hypertension to Coronary Atherosclerosis and Cardiac Events in Patients With Coronary Computed Tomographic Angiography.

Authors:  Rine Nakanishi; Lohendran Baskaran; Heidi Gransar; Matthew J Budoff; Stephan Achenbach; Mouaz Al-Mallah; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Kavitha Chinnaiyan; Benjamin J W Chow; Augustin DeLago; Martin Hadamitzky; Joerg Hausleiter; Ricardo Cury; Gudrun Feuchtner; Yong-Jin Kim; Jonathon Leipsic; Philipp A Kaufmann; Erica Maffei; Gilbert Raff; Leslee J Shaw; Todd C Villines; Allison Dunning; Hugo Marques; Gianluca Pontone; Daniele Andreini; Ronen Rubinshtein; Jeroen Bax; Erica Jones; Niree Hindoyan; Millie Gomez; Fay Y Lin; James K Min; Daniel S Berman
Journal:  Hypertension       Date:  2017-06-12       Impact factor: 10.190

6.  Hypertension in chronic kidney disease: role of ambulatory blood pressure monitoring.

Authors:  Rene G VanDeVoorde; Mark M Mitsnefes
Journal:  Prog Pediatr Cardiol       Date:  2015-12-17

7.  Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study.

Authors:  Keita Noda; Munehito Ideishi; Eiichiro Tashiro; Yoshiyuki Nakashima; Mitsuhide Imamura; Masahiko Seki; Masanori Fujino; Toshimitsu Sou; Masaki Kohara; Hisashi Kanaya; Nishiki Saku; Ritsu Kamei; Misao Yamasaki; Hiroshi Sakai; Naoki Gondo; Keijiro Saku
Journal:  Curr Ther Res Clin Exp       Date:  2003-03

8.  Age-associated increases in pulmonary artery systolic pressure in the general population.

Authors:  Carolyn S P Lam; Barry A Borlaug; Garvan C Kane; Felicity T Enders; Richard J Rodeheffer; Margaret M Redfield
Journal:  Circulation       Date:  2009-05-11       Impact factor: 29.690

9.  Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association.

Authors:  Joseph T Flynn; Stephen R Daniels; Laura L Hayman; David M Maahs; Brian W McCrindle; Mark Mitsnefes; Justin P Zachariah; Elaine M Urbina
Journal:  Hypertension       Date:  2014-03-03       Impact factor: 10.190

10.  Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD.

Authors:  Francesco Antonio Benedetto; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2008-01-09       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.